MK-1167 for Safety in Healthy Adults
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to assess the safety of a new drug, MK-1167, and determine its tolerability in healthy adults. Participants will receive either MK-1167 or a placebo (a pill with no active drug) for comparison. The trial seeks healthy individuals with a BMI between 18 and 32 who have not used nicotine products in the past three months. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.
Is there any evidence suggesting that MK-1167 is likely to be safe for humans?
Research has shown that MK-1167 has been tested on healthy adult men to assess its effects on brain chemicals. This study found no major safety issues. Another study is evaluating the safety of MK-1167 in older adults without Alzheimer's. So far, this treatment appears well-tolerated. As this trial is in the early stages, it primarily focuses on safety, with MK-1167 being closely monitored for any unexpected side effects.12345
Why do researchers think this study treatment might be promising?
Researchers are excited about MK-1167 because it offers a new approach by being administered orally, which might make it more convenient compared to some existing treatments for similar conditions that require injections or more complex delivery methods. MK-1167 could potentially offer benefits in terms of ease of use and patient compliance. While most current treatments may take longer to show effects, MK-1167 aims to deliver results more swiftly, which is an exciting prospect for both patients and healthcare providers.
What evidence suggests that MK-1167 might be an effective treatment for safety in healthy adults?
Research has shown that MK-1167 might improve memory and thinking in people with Alzheimer's disease. Studies have examined how MK-1167 affects certain brain chemicals important for learning and memory. Early results suggest that MK-1167 can change brain activity in ways that might help with memory problems. However, more research is needed to confirm these effects and ensure the treatment's safety. In this trial, participants will receive either MK-1167 or a placebo to further evaluate its safety in healthy adults.24678
Who Is on the Research Team?
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Are You a Good Fit for This Trial?
This trial is for healthy adults who have a BMI between 18 and 32, may be smokers or have used nicotine products recently. It's not suitable for those with significant health issues in various body systems like the heart, liver, or kidneys.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive MK-1167 or placebo orally to evaluate safety and tolerability
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- MK-1167
Trial Overview
The study is testing MK-1167 to see if it's safe and how well people can handle it. Participants will either receive MK-1167 or a placebo (a substance with no active drug) to compare effects.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
MK-1167 administered orally
Placebo for MK-1167 administered orally
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merck Sharp & Dohme LLC
Lead Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University
Citations
A Clinical Trial to Compare Forms of MK-1167 in Healthy ...
Is a smoker and/or has used nicotine or nicotine-containing products within the past 3 months. Ages Eligible for Study. 18 Years to 60 Years ( Adult ).
A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010)
The goal of this trial is to learn about the safety of MK-1167 and if people tolerate it. Official Title. A Multiple Dose Study to Evaluate ...
3.
msd.com
msd.com/news/msd-showcases-data-for-alzheimers-disease-candidates-mk-2214-and-mk-1167-at-ctad-2025/MSD Showcases Data for Alzheimer's Disease Candidates ...
The trial assessed the effect of single doses of MK-1167 on glutamate metabolism in the prefrontal cortex of healthy adult male volunteers, as ...
Mk-1167 – Application in Therapy and Current Clinical ...
The main goals of the MK-1167 clinical trials are to determine if it can improve memory and thinking in people with Alzheimer's disease, assess its safety ...
5.
trial.medpath.com
trial.medpath.com/clinical-trial/8f0a080c5408500c/nct07266818-mk-1167-safety-pk-qtc-healthy-adultsA Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010)
The goal of this trial is to learn about the safety of MK-1167 and if people tolerate it.
Efficacy and Safety of MK-1167 in Participants With ...
Inclusion Criteria: Reports a history of cognitive and functional decline with gradual onset and slow progression for at least 1 year before Screening, ...
A Study to Evaluate the Efficacy and Safety of MK-1167 in ...
The goals of this study are to learn: If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo ...
Merck Showcases Data for Alzheimer's Disease ...
The trial assessed the effect of single doses of MK-1167 on glutamate metabolism in the prefrontal cortex of healthy adult male volunteers, as ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.